Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2

Brain reserve contributes to distinguishing preclinical Alzheimer’s stages 1 and 2

Abstract Background In preclinical Alzheimer’s disease, it is unclear why some individuals with amyloid pathologic change are asymptomatic (stage 1), whereas others experience subjective cognitive decline (SCD, stage 2). Here, we examined the association of stage 1 vs. stage 2 with structural brain...

Full description

Bibliographic Details
Main Authors: Zerrin Yildirim, Firuze Delen, David Berron, Hannah Baumeister, Gabriel Ziegler, Hartmut Schütze, Wenzel Glanz, Laura Dobisch, Oliver Peters, Silka Dawn Freiesleben, Luisa-Sophie Schneider, Josef Priller, Eike Jakob Spruth, Anja Schneider, Klaus Fliessbach, Jens Wiltfang, Björn-Hendrik Schott, Dix Meiberth, Katharina Buerger, Daniel Janowitz, Robert Perneczky, Boris-Stephan Rauchmann, Stefan Teipel, Ingo Kilimann, Christoph Laske, Matthias H. Munk, Annika Spottke, Nina Roy, Michael Heneka, Frederic Brosseron, Michael Wagner, Sandra Roeske, Alfredo Ramirez, Michael Ewers, Peter Dechent, Stefan Hetzer, Klaus Scheffler, Luca Kleineidam, Steffen Wolfsgruber, Renat Yakupov, Matthias Schmid, Moritz Berger, Hakan Gurvit, Frank Jessen, Emrah Duzel
Format: Article
Language:English
Published: BMC 2023-02-01
Series:Alzheimer’s Research & Therapy
Subjects:
Alzheimer’s disease (AD)
Brain reserve
Subjective cognitive decline (SCD)
Cerebrospinal fluid (CSF)
Amyloid pathologic change
Aß42/40
Online Access:https://doi.org/10.1186/s13195-023-01187-9

Internet

https://doi.org/10.1186/s13195-023-01187-9

Similar Items